Breaking Finance News

Zacks Investment Research upgraded Acceleron Pharma Inc (NASDAQ:XLRN) to Hold in a report released today.

Yesterday Acceleron Pharma Inc (NASDAQ:XLRN) traded 2.43% higher at $24.65. The company’s 50-day moving average is $25.11 and its 200-day moving average is $30.77. The last closing price is down -17.94% from the 200-day moving average, compared to the S&P 500 which has increased 0.06% over the same time. 653,448 shares of the stock were exchanged, up from an average trading volume of 422,721

Zacks Investment Research has upgraded Acceleron Pharma Inc (NASDAQ:XLRN) to Hold in a report released on 02/10/2017.

See Chart Below

Acceleron Pharma Inc (NASDAQ:XLRN)

Acceleron Pharma Inc has a 52 week low of $22.67 and a 52 week high of $41.69 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 9 brokers have issued a report on the stock. The consensus target price is $47.33 with 4 brokers rating the stock a strong buy, 4 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Acceleron Pharma Inc (NASDAQ:XLRN)

Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company's pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.